Olanzapine-Induced Rapid Weight Gain and Metabolic Disorders: A Case Series.

Authors

Michal Smogur, Séverine Crettol, Céline Dubath, Frederik Vandenberghe, Georgios Schoretsanitis, Philippe Conus, Chin Bin Eap, Nicolas Ansermot

Published in

Psychopharmacology bulletin. Volume 56. Issue 4 Suppl 1. Pages 124-133. Sep 18, 2026.

Abstract

Olanzapine is an atypical antipsychotic drug associated with a high risk of weight gain and metabolic disorders. This condition represents both a major health risk for patients and a therapeutic challenge in psychiatric care. We present a series of four cases exhibiting a rapid and severe weight gain under olanzapine treatment, as well as new-onset metabolic syndrome in three of them. The evolution of these disorders after treatment modification is presented for three cases, and strategies for mitigating the risk of metabolic complications in patients receiving antipsychotic drugs are discussed.

PMID:
42763583
Bibliographic data and abstract were imported from PubMed on 20 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.